High population immunity from prior infections and updated vaccines, combined with stable surveillance showing no rapidly dominant new strain, underpins traders' strong 86% consensus that no new COVID variant of concern will emerge before 2027. Omicron sublineages such as XFG and NB.1.8.1 currently drive most cases without meeting WHO or ECDC criteria for elevated transmissibility, severity, or immune escape. Recent monitoring of BA.3.2, which appeared in late 2025 and reached notable shares in parts of Europe, has not produced the explosive growth or clinical impact seen in earlier waves, thanks to lower fitness and broad existing protection. Ongoing genomic tracking and seasonal patterns further reduce the near-term likelihood of a concerning shift, though unexpected mutations could still alter trajectories before the deadline.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$243,960 Vol.
$243,960 Vol.
Oui
$243,960 Vol.
$243,960 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...High population immunity from prior infections and updated vaccines, combined with stable surveillance showing no rapidly dominant new strain, underpins traders' strong 86% consensus that no new COVID variant of concern will emerge before 2027. Omicron sublineages such as XFG and NB.1.8.1 currently drive most cases without meeting WHO or ECDC criteria for elevated transmissibility, severity, or immune escape. Recent monitoring of BA.3.2, which appeared in late 2025 and reached notable shares in parts of Europe, has not produced the explosive growth or clinical impact seen in earlier waves, thanks to lower fitness and broad existing protection. Ongoing genomic tracking and seasonal patterns further reduce the near-term likelihood of a concerning shift, though unexpected mutations could still alter trajectories before the deadline.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes